FDA panel throws dirt on Novartis’ would-be cardio blockbuster serelaxin

Damian Garde

After a daylong session heavy on scathing criticism, a of FDA advisers voted unanimously against approving ' in-development heart drug , casting serious doubts on the treatment's potential.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS